Patient Enrolment Update

ABVC Biopharma Provides Enrolment Update In Mid-Stage Attention Deficit Disorder Study

ABVC Biopharma (NASDAQ: ABVC) provided an update on the enrollment progress in the Phase II Part II clinical study of its ADHD candidate (ABV-1505).

VYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate

VYNE Therapeutics Inc. (NASDAQ: VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).